Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...

Last week, Regeneron announced that the FDA has accepted for review the resubmission of the BLA for odronextamab in R/R FL ...

Conference Call Information Participants may access the conference call live via webcast on the ’Investors and Media’ page of Regeneron ... and refractory (R/R) multiple myeloma (MM).

Regeneron is to accelerate efforts to sequence a tranche of 500,000 genomes, including R&D to find new drugs for Alzheimer’s and Parkinson's disease. The UK Biobank’s project to sequence ...

This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. A warm welcome to all my new ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals ... Because biotech involves expensive R&D and clinical testing, it is susceptible to shifting rate patterns.

JPMorgan lowered the firm’s price target on Regeneron (REGN) to $1,000 from $1,100 and keeps an Overweight rating on the shares. The firm expects a “messy” Q1 report for Eylea but sees the ...

Regeneron Pharmaceuticals, Inc. is a well-managed company with a diverse pipeline, but faces the likely decline in revenues from its key drug, Eylea. The loss of Eylea's patent protection has led ...

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) presented positive results from the pivotal ADEPT Phase 2/3 trial evaluating the investigational use of Dupixent in adults with moderate-to-severe ...

At the CIO 100 Symposium and Awards, Lee Rennick, executive director of CIO Communities for CIO.com, sat with Bob McCowan, SVP and CIO at Regeneron Pharmaceuticals, and discussed their award ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...